Charles S. Mgone
Research Subjects
Charles S. Mgone has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Michael Makanga
European and Developing Countries Clinical Trials Partnership (EDCTP), The Hague 2593, Netherlands
2 shared publications- Adrian John Frederick Luty
Paris University
1 shared publication - Alexander Ochem
African Network for Drugs and Diagnostics Innovation, United Nations Economic Commission for Africa, Addis Ababa, Ethiopia
1 shared publication - Alimuddin Zumla
Center for Clinical Microbiology, Institute of Infection, Immunity and Transplantation, University College London, London, UK; NIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK
1 shared publication - Anastasia Guantai
Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of Nairobi, Nairobi, Kenya
1 shared publication - Barthelemy Nyasse
University of Yaoundé, Yaoundé, Cameroon
1 shared publication
Latest Publications
- 1 January 2015
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 15 (1) , 11-13
Genesis of EDCTP2
- 1 January 2015
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 15 (1) , 11-13
Genesis of EDCTP2
- Open Access
- 27 July 2012
- Published by Springer Nature in BMC International Health and Human Rights
- Vol. 12 (1) , 11
Analysis of pan-African Centres of excellence in health innovation highlights opportunities and challenges for local innovation and financing in the continent
A pool of 38 pan-African Centres of Excellence (CoEs) in health innovation has been selected and recognized by the African Network for Drugs and Diagnostics Innovation (ANDI), through a competitive criteria based process. The process identified a number of opportunities and challenges for health R&D and innovation in the continent: i) it provides a direct evidence for the existence of innovation capability that can be leveraged to fill specific gaps in the continent; ii) it revealed a research and financing pattern that is largely fragmented and uncoordinated, and iii) it highlights the most frequent funders of health research in the continent. The CoEs are envisioned as an innovative network of public and private institutions with a critical mass of expertise and resources to support projects and a variety of activities for capacity building and scientific exchange, including hosting fellows, trainees, scientists on sabbaticals and exchange with other African and non-African institutions.
- 27 July 2012
- Published by Springer Nature in BMC International Health and Human Rights
- Vol. 12 (1) , 11
Open AccessAnalysis of pan-African Centres of excellence in health innovation highlights opportunities and challenges for local innovation and financing in the continent
A pool of 38 pan-African Centres of Excellence (CoEs) in health innovation has been selected and recognized by the African Network for Drugs and Diagnostics Innovation (ANDI), through a competitive criteria based process. The process identified a number of opportunities and challenges for health R&D and innovation in the continent: i) it provides a direct evidence for the existence of innovation capability that can be leveraged to fill specific gaps in the continent; ii) it revealed a research and financing pattern that is largely fragmented and uncoordinated, and iii) it highlights the most frequent funders of health research in the continent. The CoEs are envisioned as an innovative network of public and private institutions with a critical mass of expertise and resources to support projects and a variety of activities for capacity building and scientific exchange, including hosting fellows, trainees, scientists on sabbaticals and exchange with other African and non-African institutions.
- Open Access
- 13 December 2010
- Published by Springer Nature in Malaria Journal
- Vol. 9 (S3) , S5
Strengthening of the clinical research capacity for malaria: a shared responsibility
Lack of adequate human resource capacity, good governance, sound physical infrastructure and well-functioning systems impede economic growth in low- and middle-income countries. The heavy burden from disease compounds this. To overcome these setbacks a concerted effort needs to be taken. This requires collective effort of all including the public and private sectors from development partners and from low- and medium-income countries themselves. Specific research capacity gaps, such as lack of expertise and infrastructure to engage in upstream research and development of new products, need to be addressed. Special attention should also be given to those with more acute capacity needs and high disease burden, such as communities in conflict-affected regions. Capacity building approaches need to be innovative and responsive to needs and the ever changing scientific landscape. Therefore, for example, as the global community aims to eliminate and eventually eradicate malaria, there should be an appropriately matched effort to strengthen the capacity to meet these challenges.
- 13 December 2010
- Published by Springer Nature in Malaria Journal
- Vol. 9 (S3) , S5
Open AccessStrengthening of the clinical research capacity for malaria: a shared responsibility
Lack of adequate human resource capacity, good governance, sound physical infrastructure and well-functioning systems impede economic growth in low- and middle-income countries. The heavy burden from disease compounds this. To overcome these setbacks a concerted effort needs to be taken. This requires collective effort of all including the public and private sectors from development partners and from low- and medium-income countries themselves. Specific research capacity gaps, such as lack of expertise and infrastructure to engage in upstream research and development of new products, need to be addressed. Special attention should also be given to those with more acute capacity needs and high disease burden, such as communities in conflict-affected regions. Capacity building approaches need to be innovative and responsive to needs and the ever changing scientific landscape. Therefore, for example, as the global community aims to eliminate and eventually eradicate malaria, there should be an appropriately matched effort to strengthen the capacity to meet these challenges.
- 9 June 2010
- Published by Wiley in Tropical Medicine & International Health
- Vol. 15 (8) , 973-974
Fighting HIV/AIDS, tuberculosis and malaria: one world, one partnership
- 9 June 2010
- Published by Wiley in Tropical Medicine & International Health
- Vol. 15 (8) , 973-974
Fighting HIV/AIDS, tuberculosis and malaria: one world, one partnership
- 12 October 2009
- Published by Wiley in Tropical Medicine & International Health
- Vol. 14 (11) , 1327-1328
EDCTP: a genuine north–south partnership
- 12 October 2009
- Published by Wiley in Tropical Medicine & International Health
- Vol. 14 (11) , 1327-1328
EDCTP: a genuine north–south partnership
- 1 July 2008
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 3 (4) , 521-525
The emerging shape of a global HIV research agenda: how partnerships between Northern and Southern researchers are addressing questions relevant to both
In this review I will narrate and discuss recent North-South health research partnerships and how such partnerships are of mutual benefit to both. Globalization has shrunk the world into a virtual single community in which actions of individuals may have global repercussion. The ever-improving accessibility to fast communications through both transportation and knowledge and information exchange is making this virtual community even smaller. The current large global burden of diseases of poverty, made worse by the HIV/AIDS pandemic is a major concern for all. Although the South bears the brunt of this burden and is disproportionately adversely affected, the ill effects are global. Among these effects, include global poverty, development constraints and insecurity. It is no wonder that scientists from both north and south are working together to mitigate the effects of this scourge for the mutual benefit of all. Despite a period of 25 years since the onset of the HIV/AIDS pandemic many challenges still abound. A preventive vaccine is still illusive and care and prevention programmes not universal. To mitigate this several global initiatives and North-South partnerships are working together for the common good. Such collaborations seen in academic settings, research institutions, networks of excellence and the private sector engage in research, training and service provision. This cooperation includes discovery and evaluations of HIV vaccine candidates as well as treatment and prevention methods.
- 1 July 2008
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 3 (4) , 521-525
The emerging shape of a global HIV research agenda: how partnerships between Northern and Southern researchers are addressing questions relevant to both
In this review I will narrate and discuss recent North-South health research partnerships and how such partnerships are of mutual benefit to both. Globalization has shrunk the world into a virtual single community in which actions of individuals may have global repercussion. The ever-improving accessibility to fast communications through both transportation and knowledge and information exchange is making this virtual community even smaller. The current large global burden of diseases of poverty, made worse by the HIV/AIDS pandemic is a major concern for all. Although the South bears the brunt of this burden and is disproportionately adversely affected, the ill effects are global. Among these effects, include global poverty, development constraints and insecurity. It is no wonder that scientists from both north and south are working together to mitigate the effects of this scourge for the mutual benefit of all. Despite a period of 25 years since the onset of the HIV/AIDS pandemic many challenges still abound. A preventive vaccine is still illusive and care and prevention programmes not universal. To mitigate this several global initiatives and North-South partnerships are working together for the common good. Such collaborations seen in academic settings, research institutions, networks of excellence and the private sector engage in research, training and service provision. This cooperation includes discovery and evaluations of HIV vaccine candidates as well as treatment and prevention methods.
- Open Access
- 3 January 2008
- Published by Springer Nature in Malaria Journal
- Vol. 7 (1) , 1
Host erythrocyte polymorphisms and exposure to Plasmodium falciparum in Papua New Guinea
Background: The protection afforded by human erythrocyte polymorphisms against the malaria parasite, Plasmodium falciparum, has been proposed to be due to reduced ability of the parasite to invade or develop in erythrocytes. If this were the case, variable levels of parasitaemia and rates of seroconversion to infected-erythrocyte variant surface antigens (VSA) should be seen in different host genotypes. Methods: To test this hypothesis, P. falciparum parasitaemia and anti-VSA antibody levels were measured in a cohort of 555 asymptomatic children from an area of intense malaria transmission in Papua New Guinea. Linear mixed models were used to investigate the effect of α+-thalassaemia, complement receptor-1 and south-east Asian ovalocytosis, as well as glucose-6-phosphate dehydrogenase deficiency and ABO blood group on parasitaemia and age-specific seroconversion to VSA. Results: No host polymorphism showed a significant association with both parasite prevalence/density and age-specific seroconversion to VSA. Conclusion: Host erythrocyte polymorphisms commonly found in Papua New Guinea do not effect exposure to blood stage P. falciparum infection. This contrasts with data for sickle cell trait and highlights that the above-mentioned polymorphisms may confer protection against malaria via distinct mechanisms.
- 3 January 2008
- Published by Springer Nature in Malaria Journal
- Vol. 7 (1) , 1
Open AccessHost erythrocyte polymorphisms and exposure to Plasmodium falciparum in Papua New Guinea
Background: The protection afforded by human erythrocyte polymorphisms against the malaria parasite, Plasmodium falciparum, has been proposed to be due to reduced ability of the parasite to invade or develop in erythrocytes. If this were the case, variable levels of parasitaemia and rates of seroconversion to infected-erythrocyte variant surface antigens (VSA) should be seen in different host genotypes. Methods: To test this hypothesis, P. falciparum parasitaemia and anti-VSA antibody levels were measured in a cohort of 555 asymptomatic children from an area of intense malaria transmission in Papua New Guinea. Linear mixed models were used to investigate the effect of α+-thalassaemia, complement receptor-1 and south-east Asian ovalocytosis, as well as glucose-6-phosphate dehydrogenase deficiency and ABO blood group on parasitaemia and age-specific seroconversion to VSA. Results: No host polymorphism showed a significant association with both parasite prevalence/density and age-specific seroconversion to VSA. Conclusion: Host erythrocyte polymorphisms commonly found in Papua New Guinea do not effect exposure to blood stage P. falciparum infection. This contrasts with data for sickle cell trait and highlights that the above-mentioned polymorphisms may confer protection against malaria via distinct mechanisms.